What is Cytoo?
Cytoo is a specialized biotechnology firm at the forefront of muscle pathology research, primarily recognized for its proprietary MyoScreen platform. The company bridges the gap between basic research and clinical application by providing physiologically relevant cellular models, including its signature CYTOOchips and CYTOOplates. These tools are essential for pharmaceutical and biotechnology organizations engaged in drug target identification, validation, and functional potency assays. By focusing on genetic, metabolic, and neuromuscular disorders, Cytoo provides the high-fidelity data necessary to accelerate therapeutic discovery. Its market position is defined by its ability to offer end-to-end services, ranging from hit identification to lead profiling, effectively reducing the time and cost associated with traditional drug development cycles.
How much funding has Cytoo raised?
Cytoo has raised a total of $15.9M across 3 funding rounds:
Angel/Seed
$1.2M
Series B
$4.7M
Series C
$10M
Angel/Seed (2008): $1.2M with participation from Rhône-Alpes-Creation, Expansinvest, and CEA Valorisation
Series B (2009): $4.7M led by CEA Investissement and Auriga Partners
Series C (2011): $10M supported by Auriga Partners
Key Investors in Cytoo
Auriga Partners
Auriga Partners is a venture capital firm that focuses on investing in high-growth technology and life science companies, providing both capital and strategic guidance to support long-term scaling.
CEA Investissement
CEA Investissement is a specialized subsidiary of the CEA that focuses on financing and supporting deeptech start-ups, particularly those leveraging advanced scientific research in life sciences and microelectronics.
Expansinvest
Expansinvest is a French venture capital and private equity firm that provides capital development and transmission support to companies seeking to accelerate their commercial growth.
What's next for Cytoo?
With the successful closure of its latest financing round, Cytoo is strategically positioned to deepen its investment in R&D and expand its commercial footprint. The company is expected to leverage this capital to enhance its MyoScreen platform, potentially integrating new high-throughput capabilities to meet the increasing needs of global pharmaceutical partners. Furthermore, the firm is likely to focus on scaling its operational capacity to support a broader range of therapeutic indications. As the industry shifts toward more predictive, human-centric models, Cytoo's commitment to innovation in cellular architecture will be a key driver of its long-term value proposition. The company remains focused on maintaining its technological edge while exploring new strategic alliances that could further validate its platform in clinical settings.
See full Cytoo company page
